One of the more recent TKIs (tyrosine kinase inhibitors) used to treat CML is Bosulif (bosutinib), which has been approved in many countries for people who have resistance or intolerance to another TKI.
A great deal of attention has focused on the possibility that people with a deep response to their CML medication may be able to stop treatment at some point. But perhaps a more important question is: why keep taking a medication every day? Is this necessary, or can I take a break?
Gleevec has long been the gold standard of CML treatment. But more potent second-generation medications (Tasigna and Sprycel) can now be used as first-choice treatments instead of Gleevec. So how well do these two drugs perform in controlling CML?
People with CML who respond to a TKI (tyrosine kinase inhibitor) can expect to live a little bit longer than similarly aged people without CML in the general population, according to a new analysis by researchers at the MD Anderson Cancer Center, Houston, Texas.